Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

Heart Failure
Johnson & Johnson to Acquire V-Wave
08/20/2024
V-Wave’s Ventura® Interatrial Shunt (IAS) is a novel implantable device designed to decrease elevated left atrial pressure seen in congestive heart failure by creating a shunt between the left and right atrium, thereby reducing cardiovascular...
V-Wave’s Ventura® Interatrial Shunt (IAS) is a novel implantable device designed to decrease elevated left atrial pressure seen in congestive heart failure by creating a shunt between the left and right atrium, thereby reducing cardiovascular...
V-Wave’s Ventura® Interatrial...
08/20/2024
Cath Lab Digest
Direct Oral Anticoagulants (DOACs)
Most Blood Thinner Dosing Problems Happen After Initial Prescription
08/20/2024
“Direct oral anticoagulants may be viewed as simpler to manage than traditional blood thinners, like warfarin, but our results highlight why providers need to be consistently monitoring anticoagulant medications before a patient experiences...
“Direct oral anticoagulants may be viewed as simpler to manage than traditional blood thinners, like warfarin, but our results highlight why providers need to be consistently monitoring anticoagulant medications before a patient experiences...
“Direct oral anticoagulants may...
08/20/2024
Cath Lab Digest
Aneurysms
Study: Why Aortic Aneurysms Form at the Arch or in the Abdominal Segment
08/20/2024
In order to find out what distinguishes the repeatedly affected vascular regions from others, Daniela Wenzel and her team developed a method to specifically examine the endothelium of the aorta. “We know from other vascular diseases such as...
In order to find out what distinguishes the repeatedly affected vascular regions from others, Daniela Wenzel and her team developed a method to specifically examine the endothelium of the aorta. “We know from other vascular diseases such as...
In order to find out what...
08/20/2024
Cath Lab Digest

Advertisement

Cardiac Arrest
Can Naloxone Improve Survival Rates of Patients With Cardiac Arrest?
08/20/2024
A recent study by UC Davis Health researchers set out to assess the effects of giving naloxone administration by paramedics to patients with OHCA. The study concluded there was an association between naloxone administration, and both return...
A recent study by UC Davis Health researchers set out to assess the effects of giving naloxone administration by paramedics to patients with OHCA. The study concluded there was an association between naloxone administration, and both return...
A recent study by UC Davis...
08/20/2024
Cath Lab Digest
Treatment Pathways
Gut Microbial Pathway Identified as Target for Improved Heart Disease Treatment
08/20/2024
Cleveland Clinic News Cleveland Clinic researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The Nature Communications study found...
Cleveland Clinic News Cleveland Clinic researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The Nature Communications study found...
Cleveland Clinic...
08/20/2024
Cath Lab Digest
Genetics
Genetic Link Between Alzheimer's and Heart Disease Confirmed
08/19/2024
Researchers at Edith Cowan University's (ECU's) Centre for Precision Health have uncovered a significant genetic connection between Alzheimer's disease (AD) and several coronary artery disease (CAD) related disorders and lipid classes,...
Researchers at Edith Cowan University's (ECU's) Centre for Precision Health have uncovered a significant genetic connection between Alzheimer's disease (AD) and several coronary artery disease (CAD) related disorders and lipid classes,...
Researchers at Edith Cowan...
08/19/2024
Cath Lab Digest

Advertisement

Structural Heart Business
Genesis MedTech Announces the Sale of JC Medical, Inc to Edwards Lifesciences
08/19/2024
Genesis MedTech has sold JC Medical, Inc. to Edwards Lifesciences, including the intellectual property and commercial rights of its J-Valve® System, a transcatheter aortic valve replacement for the treatment of severe aortic regurgitation.
Genesis MedTech has sold JC Medical, Inc. to Edwards Lifesciences, including the intellectual property and commercial rights of its J-Valve® System, a transcatheter aortic valve replacement for the treatment of severe aortic regurgitation.
Genesis MedTech has sold JC...
08/19/2024
Cath Lab Digest
Vascular Closure
Haemonetics Announces Full Market Release for Vascade MVP XL Vascular Closure System
08/15/2024
The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch...
The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch...
The VASCADE MVP XL system is now...
08/15/2024
EP Lab Digest
Pulmonary Embolism
Jupiter Endovascular Announces $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism
08/15/2024
Jupiter Endovascular is developing the endoportal procedure, using Endoportal Control™ to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates...
Jupiter Endovascular is developing the endoportal procedure, using Endoportal Control™ to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates...
Jupiter Endovascular is...
08/15/2024
Cath Lab Digest

Advertisement

ACC ASIA 2024
New Study Finds Chronic High Caffeine Consumption May Heighten Risk for Cardiovascular Disease
08/15/2024
According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of caffeine per day on most days of the week could increase the susceptibility of otherwise healthy individuals to cardiovascular disease.
According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of caffeine per day on most days of the week could increase the susceptibility of otherwise healthy individuals to cardiovascular disease.
According to a new study being...
08/15/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

News

Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest
Large Bore Closure
TCT: Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal Large Hole Closure Device
10/29/2024
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure...
10/29/2024
Cath Lab Digest
Renal denervation
TCT: SPYRAL HTN-ON MED Study Shows Significant, Consistent, Long-Term Blood Pressure Lowering Effect at Two Years
10/29/2024
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step...
10/29/2024
Cath Lab Digest
EMPOWER CAD Completed Enrollment
Intravascular Lithotripsy
TCT: Shockwave Medical Completes Enrollment in All-Female Coronary IVL Study
10/28/2024
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to...
10/28/2024
Cath Lab Digest
aortic valve stenosis
TCT: Cardiawave Announces Positive Six-Month Data From Valvosoft Pivotal Study
10/28/2024
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused...
10/28/2024
Cath Lab Digest
Pulmonary Embolism
TCT: RESCUE II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis Without Post-Procedure Infusion in Treating Acute Pulmonary Embolism
10/28/2024
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular...
10/28/2024
Cath Lab Digest
EARLY TAVR
TCT: Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
10/28/2024
With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular hospitalization compared to 45.3% of the 446 patients...
With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular hospitalization compared to 45.3% of the 446 patients...
With a median follow up of 3.8...
10/28/2024
Cath Lab Digest

Advertisement

Advertisement

Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest
Large Bore Closure
TCT: Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal Large Hole Closure Device
10/29/2024
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure...
10/29/2024
Cath Lab Digest
Clinical Images
Coronary Stent and Balloon Entrapment Following Delivery Device Perforation
10/29/2024
The authors present the first reported case of stent and balloon entrapment treated by placing a new stent using the crush technique with intra-coronary optical coherence tomography.
The authors present the first reported case of stent and balloon entrapment treated by placing a new stent using the crush technique with intra-coronary optical coherence tomography.
The authors present the first...
10/29/2024
Journal of Invasive Cardiology
Renal denervation
TCT: SPYRAL HTN-ON MED Study Shows Significant, Consistent, Long-Term Blood Pressure Lowering Effect at Two Years
10/29/2024
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step...
10/29/2024
Cath Lab Digest
EMPOWER CAD Completed Enrollment
Intravascular Lithotripsy
TCT: Shockwave Medical Completes Enrollment in All-Female Coronary IVL Study
10/28/2024
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to...
10/28/2024
Cath Lab Digest
aortic valve stenosis
TCT: Cardiawave Announces Positive Six-Month Data From Valvosoft Pivotal Study
10/28/2024
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused...
10/28/2024
Cath Lab Digest
Pulmonary Embolism
TCT: RESCUE II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis Without Post-Procedure Infusion in Treating Acute Pulmonary Embolism
10/28/2024
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular...
10/28/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use